Search | Clinical Trials Finder

Conditions: Irritability Associated With Autism Spectrum Disorder
Interventions: KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 29
States / cities: Dothan, Alabama • Phoenix, Arizona • Anaheim, California + 25 more

Conditions: Alzheimer Disease, Agitation
Interventions: KarXT, KarX-EC; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 42
States / cities: Chandler, Arizona • Scottsdale, Arizona • Anaheim, California + 37 more

Conditions: Schizophrenia
Interventions: KarXT (xanomeline and trospium); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 6,876 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: SCHIZOPHRENIA 1 (Disorder), Schizoaffecitve Disorder
Interventions: Xanomeline and trospium chloride (KarXT); Drug
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Cocaine Use Disorder (CUD)
Interventions: Cobenfy, Placebo; Drug
Lead sponsor: Joshua A. Lile, Ph.D.; Other
Eligibility: 18 Years to 60 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Irritability Associated With Autism Spectrum Disorder
Interventions: KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 5 Years to 17 Years
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 23
States / cities: Phoenix, Arizona • Glendale, California • Los Angeles, California + 19 more

Conditions: Alzheimer's Disease
Interventions: Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 426 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 42
States / cities: Chandler, Arizona • Garden Grove, California • Long Beach, California + 35 more

Conditions: Bipolar-I Disorder With Mania or Mania With Mixed Features
Interventions: KarXT, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 23
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 19 more

Conditions: Schizophrenia
Interventions: Xanomeline and Trospium Chloride Capsules; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 34
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Anaheim, California + 27 more

Conditions: Healthy Volunteers
Interventions: Xanomeline/ Trospium Chloride; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 3
States / cities: Anaheim, California • Lenexa, Kansas • San Antonio, Texas

Conditions: Schizophrenia
Interventions: Xanomeline and Trospium Chloride Capsules; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 290 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 56
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 44 more

Conditions: Bipolar Disorder Type I With Mania
Interventions: KarXT, Lithium, Valproate, Lamotrigine; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 61
States / cities: Glendale, Arizona • Scottsdale, Arizona • Tucson, Arizona + 49 more

Conditions: Mania, Bipolar Disorder
Interventions: Xanomeline/Trospium Chloride, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 424 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 20
States / cities: Bentonville, Arkansas • Little Rock, Arkansas • Bellflower, California + 17 more

Conditions: Schizophrenia
Interventions: Xanomeline and Trospium Chloride Capsules, Placebo; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 396 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 79
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Anaheim, California + 61 more

Conditions: Schizophrenia
Interventions: Xanomeline and Trospium Chloride Capsules; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 566 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 116
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Anaheim, California + 56 more

Conditions: Psychosis Associated With Alzheimer's Disease
Interventions: KarXT, Placebo; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 410 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 59
States / cities: Homewood, Alabama • Phoenix, Arizona • Encino, California + 38 more

Conditions: Epilepsy, Essential Tremor, Seizures, Memory Consolidation, Memory Disorders, Memory Replay, Memory Encoding, Cognitive Control, Motor Abilities
Interventions: Cobenfy KarXT pill (50/20 mg), Placebo; Drug
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Schizophrenia Disorders
Interventions: Xanomeline and Trospium Chloride; Drug
Lead sponsor: Collaborative Neuroscience Research, LLC; Network
Eligibility: 18 Years to 65 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025
U.S. locations: 7
States / cities: Bellflower, California • Garden Grove, California • Riverside, California + 4 more

Conditions: Psychosis Associated With Alzheimer's Disease
Interventions: KarXT; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 147
States / cities: Homewood, Alabama • Chandler, Arizona • Gilbert, Arizona + 92 more

Conditions: Schizophrenia
Interventions: xanomeline tartrate, Trospium chloride; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy Volunteers
Interventions: KarXT, Midazolam, Fexofenadine, Digoxin; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 62 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Bipolar Disorder Type I With Mania or Mania With Mixed Features
Interventions: KarXT, Placebo; Drug · Other
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 274 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 28
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Culver City, California + 23 more

Conditions: Schizophrenia
Interventions: Xanomeline and Trospium Chloride Capsules; Drug
Lead sponsor: Karuna Therapeutics, Inc., a Bristol Myers Squibb company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 5
States / cities: Atlanta, Georgia • Louisville, Kentucky • Columbus, Ohio + 2 more

Conditions: Alzheimer Disease, Psychosis
Interventions: KarXT, KarX-EC, KarXT + KarX-EC Arm Matching Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 55 Years to 90 Years
Enrollment: 325 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 6
States / cities: Gilbert, Arizona • Chino, California • Naples, Florida + 2 more

Search by objective public record fields.

A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism

A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

Real-world Patient Characteristics, Treatment Patterns, and Healthcare Utilization Among KarXT Users

A PET/MRI Study of Cobenfy on Dopamine Transmission in Schizophrenia

The Impact of Cobenfy Maintenance on Cocaine's Effects

A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder

A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder

An Extension Study to Assess Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-4)

A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants

An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

A Study to Assess the Long-term Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-3)

A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine

A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia

An Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of KarXT in Adult Patients With Schizophrenia (EMERGENT-5)

A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)

Human Cognition During Surgery: Stimulation-based and Cholinergic Modulation

An 8-week Open-label Study of an Accelerated and Slower Switching to Xanomeline/Trospium Following Atypical Antipsychotic Treatment in Participants With Schizophrenia

Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)

Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium

A Study to Evaluate the Effects of KarXT on the Drug Levels of Midazolam, Fexofenadine, and Digoxin

A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)

An Open-label Study to Assess the Long-term Safety, Tolerability, Effectiveness, and Durability of Effect of KarXT in Patients With DSM-5 Diagnosis of Schizophrenia

A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)